The Future of CMC Regulatory Submissions: Streamlining Activities Using Structured Content and Data Management.

Artificial intelligence Automation Database(s) Machine learning Regulatory science Standards

Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
05 2022
Historique:
received: 26 08 2021
revised: 29 09 2021
accepted: 29 09 2021
pubmed: 6 10 2021
medline: 21 4 2022
entrez: 5 10 2021
Statut: ppublish

Résumé

Recent advancements in data engineering, data science, and secure cloud storage can transform the current state of global Chemistry, Manufacturing, and Controls (CMC) regulatory activities to automated online digital processes. Modernizing regulatory activities will facilitate simultaneous global submissions and concurrent collaborative reviews, significantly reducing global licensing timelines and variability in globally registered product details. This article describes advancements made within the pharmaceutical industry from theoretical concepts to utilization of structured content and data in CMC submissions. The term Structured Content and Data Management (SCDM) outlines the end-to-end scientific data lifecycle from capture in source systems, aggregation into a consolidated repository, and transformation into semantically structured blocks with metadata defining relationships between scientific data and business contexts. Automation of regulatory authoring (termed Structured Content Authoring) is feasible because SCDM makes data both human and machine readable. It will offer health authorities access to the digital data beyond the current standard of PDF documents and, for a review process, SCDM would "enrich the effectiveness, efficiency, and consistency of regulatory quality oversight" (Yu et al., 2019). SCDM is a novel solution for content and data management in regulatory submissions and can enable faster access to critical therapies worldwide.

Identifiants

pubmed: 34610323
pii: S0022-3549(21)00532-3
doi: 10.1016/j.xphs.2021.09.046
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1232-1244

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Kabir Ahluwalia (K)

Department of Global Regulatory Affairs - CMC, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA; University of Southern California, School of Pharmacy, 1985 Zonal Ave, Los Angeles, CA 90089, USA.

Michael J Abernathy (MJ)

Department of Global Regulatory Affairs - CMC, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.

Jill Beierle (J)

Department of Global Regulatory Affairs - CMC, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.

Nina S Cauchon (NS)

Department of Global Regulatory Affairs - CMC, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. Electronic address: ncauchon@amgen.com.

David Cronin (D)

Cognition Corporation, 24 Hartwell Ave, Lexington, MA 02421, USA.

Sheetal Gaiki (S)

Biotherapeutic Development & Supply, Janssen Pharmaceuticals, 1000 Route 202 South, Raritan, NJ 08807, USA.

Andrew Lennard (A)

Department of Global Regulatory Affairs - CMC; Amgen Ltd, 1 Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom.

Pradeep Mady (P)

Product Quality Management, Janssen Pharmaceuticals, 1000 Route 202 South, Raritan, NJ 08807, USA.

Mike McGorry (M)

Biotherapeutic Development & Supply, Janssen Pharmaceuticals, Barnahely, Ringaskiddy, Co.Cork, Ireland.

Kathleen Sugrue-Richards (K)

Department of Global Regulatory Affairs - CMC, Amgen Inc., 40 Technology Way West Greenwich, RI 02817, USA.

Gang Xue (G)

Biotherapeutic Development & Supply, Janssen Pharmaceuticals, 200 Great Valley Pkwy, Malvern, PA 10355, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH